Haisco Pharmaceutical Group Co., Ltd.
002653
Classement en actions
#2010
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Prix de l'action
$9.03
Capitalisation boursière
$10.30B
Changement (1 jour)
4.55%
Changement (1 an)
24.15%
Pays
CN
Échange Haisco Pharmaceutical Group Co., Ltd. (002653)
Catégorie
Healthcare
Bénéfices pour Haisco Pharmaceutical Group Co., Ltd. (002653)
Bénéfices en Jun 2026 TTM : $144.70M
Selon les derniers rapports financiers de Haisco Pharmaceutical Group Co., Ltd., les bénéfices actuels de l'entreprise sont de $144.70M. En 2023, l'entreprise a réalisé un bénéfice de $42.74M, une diminution par rapport à celui de 2022 qui était de $53.15M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Haisco Pharmaceutical Group Co., Ltd. de 2008 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $144.70M | 128.15% |
| 2024 | $63.43M | 48.41% |
| 2023 | $42.74M | -19.59% |
| 2022 | $53.15M | -33.86% |
| 2021 | $80.36M | -23.86% |
| 2020 | $105.54M | 34.49% |
| 2019 | $78.47M | 67.09% |
| 2018 | $46.96M | 18.07% |
| 2017 | $39.78M | -42.90% |
| 2016 | $69.65M | 8.93% |
| 2015 | $63.94M | -21.50% |
| 2014 | $81.46M | -13.14% |
| 2013 | $93.78M | 21.75% |
| 2012 | $77.03M | 31.46% |
| 2011 | $58.59M | 6.29% |
| 2010 | $55.13M | 19.25% |
| 2009 | $46.23M | 45.27% |
| 2008 | $31.82M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 3,545.32% |
US
|
|
| $-3.09B | -2,233.33% |
US
|
|
| $-4.02B | -2,875.47% |
AU
|
|
| $1.95B | 1,248.04% |
NL
|
|
| - | - |
CH
|
